Cosopt is a prescription ophthalmic solution for adults with raised intraocular pressure. It is used for open-angle glaucoma and ocular hypertension when one pressure-lowering medicine is not enough. Dorzolamide and timolol lower aqueous humour production through separate pharmacological pathways.
Cosopt is a sterile eye-drop solution supplied in a bottle containing 5 ml. Its active ingredients are dorzolamide hydrochloride and timolol maleate. The combination is used to lower intraocular pressure in adults with open-angle glaucoma or ocular hypertension. The dose is stated on the pack — follow the leaflet.
Cosopt is a sterile eye-drop solution supplied in a bottle containing 5 ml. Its active ingredients are dorzolamide hydrochloride and timolol maleate. The dose is stated on the pack — follow the leaflet.
The standard adult dose is one drop of Cosopt in the affected eye or eyes twice daily, approximately 12 hours apart. The exact treatment plan depends on the ophthalmologist’s pressure target and whether other eye medicines are also prescribed.
The bottle is intended for ophthalmic use only. Do not swallow the solution or apply it to the skin.
Dorzolamide inhibits carbonic anhydrase in the ciliary processes, reducing bicarbonate formation and aqueous humour production. Timolol blocks beta-adrenergic receptors in the ciliary body, reducing aqueous humour secretion. Through these separate pathways, the combination lowers intraocular pressure.
Open-angle glaucoma usually progresses slowly. Many patients have no pain or obvious visual change during the early stages, so pressure checks and optic-nerve assessment remain central to treatment. Ocular hypertension means that intraocular pressure is above the usual range without established glaucomatous damage; treatment decisions depend on pressure level, optic-nerve appearance, corneal thickness, age, and other risk factors.
The Ocular Hypertension Treatment Study showed that lowering pressure can reduce the risk of developing glaucomatous damage in selected higher-risk patients [1]. Cosopt does not restore optic-nerve tissue already lost. Its role is pressure control and protection against further damage.
Cosopt offers two mechanisms in one bottle. Clinicians may choose it when pressure remains above target with a single agent, when separate medicines create a complicated routine, or when a fixed combination improves adherence.
| Treatment category | Main mechanism | Typical clinical role |
|---|---|---|
| Cosopt | Carbonic anhydrase inhibition plus beta-blockade | Dual-mechanism pressure reduction |
| Prostaglandin analogue | Increases aqueous humour outflow | Common first-line option for many patients |
| Beta-blocker monotherapy | Reduces aqueous humour production | Useful when suitable, though systemic effects limit use |
Prostaglandin analogues often provide strong pressure reduction with once-daily dosing, though eyelash growth, iris pigmentation, conjunctival redness, and periocular skin changes can occur. Beta-blocker monotherapy avoids adding a second topical mechanism but may be insufficient when pressure remains elevated.
A fixed combination can reduce the number of separate bottles and may improve adherence compared with multiple independent dosing schedules. The trade-off is that the patient receives timolol even when beta-blockade becomes unsuitable because of asthma, slow pulse, or conduction disease. Guidance from the European Glaucoma Society supports choosing treatment according to pressure target, disease severity, tolerability, and systemic health rather than using one regimen for every patient [2].
Cosopt is contraindicated or requires avoidance in people with:
Timolol can worsen bronchospasm and slow cardiac conduction. Dorzolamide is a sulfonamide derivative, so a history of serious sulfonamide hypersensitivity requires careful evaluation.
Interactions also matter. Oral beta-blockers, calcium-channel blockers, antiarrhythmics, digitalis, clonidine, and medicines that lower blood pressure may increase cardiovascular effects. Other carbonic anhydrase inhibitors can increase the risk of additive systemic effects. Antidepressants that inhibit monoamine oxidase and medicines affecting catecholamine handling may also require review.
Tell the prescriber about insulin or other glucose-lowering treatment. Beta-blockers can mask some warning signs of low blood glucose, such as a rapid heartbeat.
Cosopt is not suitable for everyone. NOT for you if you have asthma, a very slow pulse, or certain heart-conduction problems unless a clinician specifically advises otherwise. The prescriber needs a complete history of respiratory disease, heart rhythm problems, circulation disorders, kidney disease, liver disease, allergies, and current medicines.
Contact lenses require removal before dosing because some formulations may contain preservatives that can be absorbed by soft lenses.
Local reactions are the most familiar effects of Cosopt. Burning, stinging, itching, tearing, blurred vision, a foreign-body sensation, or redness may occur shortly after application. Blurred vision should settle before driving or operating machinery.
Systemic effects can arise because dorzolamide and timolol may enter the circulation through the eye and nasal passages. Possible effects include:
Seek urgent medical attention for fainting, severe breathing difficulty, marked wheezing, chest pain, a very slow heartbeat, facial swelling, or sudden vision changes. These symptoms may indicate a serious cardiovascular, respiratory, allergic, or ocular reaction.
Several routine errors can reduce treatment quality:
One drop is generally enough to fill the conjunctival sac. A second drop mostly spills onto the cheek or drains through the nose, increasing waste and potentially increasing systemic absorption.
In clinical practice, doctors often view Cosopt as a useful step when one pressure-lowering drop has not reached the target. The fixed combination avoids asking a patient to remember two separate bottles with different schedules, which can be valuable for older adults or people using several medicines.
An ophthalmologist will usually judge success by measured pressure, optic-nerve findings, visual-field stability, and tolerance. Feeling no difference does not prove that the treatment is unnecessary. Glaucoma can remain symptom-free while damage continues.
The main limitation is timolol exposure. A patient with asthma, wheezing, a slow pulse, or heart block may need a different treatment strategy. Prescribers also consider kidney function because dorzolamide has a systemic elimination pathway.
Dorzolamide and timolol begin acting after topical administration, with pressure reduction commonly detectable within about one hour. The size of the response varies with baseline pressure, drainage function, previous treatment, and adherence. The American Academy of Ophthalmology described the combination's sustained dosing-interval effect in its 2020 guidance [3]. Pressure response still varies between patients. Follow-up measurements are needed to confirm that the treatment meets the prescribed target.
Apply the missed dose when remembered unless the next scheduled dose is close. In that situation, skip the missed application and return to the usual timetable. Do not double the dose, because extra drops do not reliably improve pressure control and may increase unwanted local or systemic exposure. The 2023 U.S. Food and Drug Administration product information uses this same practical approach for ophthalmic medicines in the Cosopt class [4].
Contact lenses should be removed before applying Cosopt. They can usually be replaced after at least 15 minutes, provided the eye is comfortable and vision is clear. Preservatives in multi-dose ophthalmic products can accumulate in soft lenses and irritate the ocular surface. Guidance from the EMA in 2024 continues to treat lens removal as a standard precaution for preserved eye drops.
Several glaucoma treatments can be used together, but the timing must be planned. Leave at least 10 minutes between different ophthalmic drops so that the first medicine is not washed out. Ointments should generally be applied after liquid drops. The American Academy of Ophthalmology guidance from 2020 supports tailoring combination treatment to pressure targets, eye-surface tolerance, and systemic contraindications.
Pregnancy and breastfeeding require an individual risk assessment because timolol and dorzolamide can have systemic exposure after eye application. The potential effect on the fetus or breastfed infant depends on maternal treatment, timing, and alternatives. The prescriber should know about pregnancy, planned pregnancy, or breastfeeding before Cosopt is started. WHO medicine-safety principles published in 2023 support selecting the lowest-risk treatment that still meets the clinical goal.
Cosopt lowers intraocular pressure, which can reduce the risk of progressive optic-nerve damage in suitable patients. It cannot reverse established nerve damage or restore lost visual-field areas. Long-term benefit depends on reaching the pressure target, using the drops consistently, and attending scheduled examinations. The Ocular Hypertension Treatment Study follow-up published by the National Eye Institute in 2002 remains a key reference for the relationship between pressure reduction and glaucoma risk.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Cosopt is supplied as eye drops in a bottle. Keep the container closed between applications and avoid placing the tip on any surface. Contamination can introduce microorganisms into an ophthalmic solution and increase the risk of eye infection.
My pressure was still above target with one drop. Cosopt stung for about a minute at first, then the irritation became easier to tolerate. The biggest improvement was having one bottle instead of remembering two separate morning doses.
The drops caused a bitter taste and occasional blurred vision after application. Pressing near the nose helped with the taste. My follow-up pressure was better, although I needed a reminder for the evening dose.
I felt more tired during the first few weeks and noticed a slower pulse when walking upstairs. My ophthalmologist reviewed my heart tablets and changed the treatment. The pressure control had been good, but the systemic symptoms were not comfortable.
The bottle was simple to use once I stopped touching the tip to my lashes. I had mild burning at the beginning, but it settled. I still needed regular visual-field testing because I could not feel whether the pressure was high.
